Matinas BioPharma (MTNB) stock price, revenue, and financials

Matinas BioPharma market cap is $285.5 m, and annual revenue was $89.81 k in FY 2019

$285.5 M

MTNB Mkt cap, 08-Feb-2021

$95.8 K

Matinas BioPharma Revenue Q3, 2020
Matinas BioPharma Net income (Q3, 2020)-5.4 M
Matinas BioPharma EBIT (Q3, 2020)-5.6 M
Matinas BioPharma Cash, 30-Sept-20207.1 M
Matinas BioPharma EV282.3 M

Matinas BioPharma Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

2.6m3.2m4.1m7.3m12.4m22.2m

Prepaid Expenses

114.4k231.8k304.4k502.0k538.6k1.9m

Current Assets

2.8m3.6m4.6m8.0m13.1m29.9m

PP&E

340.0k377.7k356.1k1.6m2.0m1.7m

Goodwill

1.3m1.3m1.3m1.3m1.3m

Total Assets

3.4m8.4m9.8m14.4m19.9m40.2m

Accounts Payable

271.2k497.8k475.6k582.9k295.7k679.3k

Dividends Payable

1.2m

Short-term debt

44.4k11.3k128.0k197.2k283.1k423.7k

Current Liabilities

1.1m1.1m1.4m2.2m2.8m3.1m

Long-term debt

15.3k16.4k67.7k107.7k3.8m

Non-Current Liabilities

961.6k4.1m

Total Debt

59.7k11.3k118.0k170.2k199.8k4.2m

Total Liabilities

1.1m2.3m2.7m3.7m3.8m7.2m

Common Stock

3.2k5.7k5.8k9.3k11.3k16.3k

Preferred Stock

6.1m

Additional Paid-in Capital

16.3m29.3m36.2m56.2m72.3m113.4m

Retained Earnings

(14.1m)(23.2m)(35.2m)(51.3m)(65.9m)(84.4m)

Total Equity

2.2m6.1m7.1m10.7m16.1m33.1m

Debt to Equity Ratio

0 x0 x0 x0 x0 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x

Financial Leverage

1.5 x1.4 x1.4 x1.4 x1.2 x1.2 x

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

8.6m6.6m5.0m4.6m6.6m4.4m1.7m578.3k6.2m15.8m11.3m9.0m4.3m8.9m6.6m39.4m36.8m32.7m10.1m14.9m7.1m

Accounts Receivable

89.8k

Prepaid Expenses

87.6k38.1k108.1k93.6k115.0k342.2k138.0k139.6k254.0k803.0k317.3k1.0m475.3k249.8k692.4k391.0k494.6k1.4m2.7m1.1m2.2m

Current Assets

8.6m6.7m5.1m4.8m6.9m4.9m1.9m773.5k6.5m16.8m11.7m10.2m4.9m9.3m7.5m39.9m37.4m34.3m74.0m69.2m65.2m

PP&E

364.9k361.6k357.7k339.0k363.2k365.5k364.8k382.5k368.8k344.2k1.2m1.5m1.7m1.8m2.1m1.5m1.8m1.8m1.7m1.6m1.6m

Goodwill

1.4m1.4m1.4m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m1.3m

Total Assets

9.3m7.4m5.8m9.8m11.9m9.9m6.7m5.6m11.3m22.0m17.8m16.5m11.5m16.0m14.4m50.6m48.2m44.8m84.1m79.1m74.8m

Accounts Payable

242.3k281.1k211.8k466.6k745.6k282.1k620.6k475.9k209.5k1.2m453.2k341.6k473.5k497.4k303.4k394.7k548.1k685.8k953.3k494.6k373.1k

Dividends Payable

1.2m1.2m1.2m

Short-term debt

44.5k43.8k44.1k44.6k33.6k32.5k9.6k198.6k57.4k18.8k316.9k94.3k52.7k403.1k79.9k440.8k443.8k417.9k

Current Liabilities

673.4k872.2k1.0m1.3m1.1m872.8k1.3m1.3m1.4m2.0m1.3m1.9m1.0m1.5m2.6m3.1m3.5m2.6m2.5m2.4m2.8m

Long-term debt

43.6k33.6k22.5k20.7k19.0k13.8k51.4k47.9k116.0k103.0k122.6k4.1m4.0m3.9m3.6m3.5m3.4m

Non-Current Liabilities

4.5m4.3m4.2m4.0m3.9m3.8m

Total Debt

88.2k77.4k66.5k44.6k10.0k32.5k30.3k188.9k47.2k70.1k297.9k42.6k155.7k319.7k79.9k4.0m3.9m4.1m4.0m3.8m

Total Liabilities

717.0k905.8k1.0m3.4m3.2m2.9m2.5m2.6m2.6m3.2m2.6m3.7m3.1m3.5m4.1m7.6m7.8m6.8m6.5m6.3m6.6m

Common Stock

3.2k3.2k3.2k4.7k5.7k5.7k5.8k5.8k5.8k9.1k9.2k9.3k9.4k9.4k9.8k14.3k14.4k16.3k19.7k19.9k19.9k

Preferred Stock

6.1m6.0m4.0m4.0m4.0m

Additional Paid-in Capital

14.6m14.8m15.7m23.0m27.6m28.1m29.6m30.0m35.9m52.5m53.0m54.7m58.2m58.8m60.9m103.3m104.6m112.7m162.5m164.1m165.0m

Retained Earnings

(6.0m)(8.4m)(11.0m)(16.6m)(19.0m)(21.2m)(25.4m)(27.1m)(33.3m)(39.7m)43.6m(47.6m)(55.4m)(58.8m)(62.3m)(70.0m)(73.8m)(78.8m)(89.4m)(95.7m)(101.2m)

Total Equity

8.6m6.5m4.7m6.4m8.6m7.0m4.2m3.0m8.7m18.9m15.2m12.8m8.4m12.5m10.3m43.0m40.4m38.0m77.6m72.8m68.2m

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0.1 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0 x0.1 x

Financial Leverage

1.1 x1.1 x1.2 x1.5 x1.4 x1.4 x1.6 x1.9 x1.3 x1.2 x1.2 x1.3 x1.4 x1.3 x1.4 x1.2 x1.2 x1.2 x1.1 x1.1 x1.1 x

Matinas BioPharma Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(10.2m)(9.1m)(7.6m)(15.5m)(14.1m)(17.4m)

Depreciation and Amortization

41.6k43.5k52.6k100.6k218.3k206.0k

Accounts Payable

(125.6k)(73.7k)(22.2k)107.3k(287.2k)383.7k

Cash From Operating Activities

(8.0m)(7.8m)(6.1m)(11.5m)(10.3m)(14.1m)

Purchases of PP&E

(288.5k)(76.2k)(942.2k)(535.9k)(405.6k)

Cash From Investing Activities

(288.5k)(5.4k)(942.2k)(535.9k)(6.0m)

Short-term Borrowings

(10.0k)(144.3k)(330.8k)(370.1k)(199.8k)

Long-term Borrowings

(48.4k)(15.9k)(17.1k)(59.2k)(81.7k)

Cash From Financing Activities

8.5m7.0m15.6m15.9m29.9m

Net Change in Cash

(8.2m)636.3k878.5k3.2m5.0m9.7m

Quarterly

USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

(2.1m)(4.6m)(7.2m)(2.6m)(5.0m)(7.1m)(2.2m)(3.9m)(5.7m)(4.5m)(8.5m)(11.9m)(4.1m)(7.5m)(10.5m)(4.1m)(7.4m)(11.8m)(5.0m)(10.7m)(16.1m)

Depreciation and Amortization

9.5k19.9k51.5k10.9k20.6k32.7k12.9k26.3k40.0k12.0k24.8k56.2k47.1k100.1k156.6k47.9k96.9k148.9k57.6k115.4k173.2k

Accounts Receivable

15.5k(89.8k)

Accounts Payable

(154.4k)(115.7k)(184.9k)(104.9k)174.0k(289.5k)122.7k(22.0k)(288.4k)771.9k(22.4k)(134.0k)(109.4k)(85.5k)(279.4k)99.0k252.5k390.1k274.0k(184.7k)(306.2k)

Cash From Operating Activities

(2.1m)(3.9m)(5.5m)(2.3m)(4.5m)(6.7m)(1.5m)(2.6m)(4.0m)(3.0m)(6.8m)(9.5m)(2.8m)(5.1m)(7.7m)(3.0m)(5.1m)(9.2m)(4.7m)(7.8m)(13.1m)

Purchases of PP&E

(193.3k)(257.8k)(288.5k)(4.8k)(38.7k)(53.2k)(31.1k)(789.7k)(101.9k)(260.6k)(535.9k)(14.2k)(332.2k)(405.6k)(5.7k)(5.7k)(5.7k)

Capital Expenditures

(823.9k)

Cash From Investing Activities

(193.3k)(257.8k)(288.5k)65.9k32.0k17.5k(31.1k)(789.7k)(823.9k)(101.9k)(260.6k)(535.9k)(14.2k)(332.2k)(405.6k)(55.0m)(47.0m)(49.8m)

Short-term Borrowings

(73.5k)(70.8k)(118.0k)(127.7k)(170.2k)(250.2k)(119.9k)(199.8k)(199.8k)

Long-term Borrowings

(11.3k)(13.6k)(2.4k)(9.4k)(8.0k)(20.0k)(36.8k)(20.2k)(42.3k)(61.8k)(19.9k)(36.2k)(46.9k)

Cash From Financing Activities

4.3m8.5m8.5m(11.3k)19.0k7.0m14.8m14.7m15.3m(135.7k)6.9m7.5m30.0m29.9m29.8m47.4m47.4m47.5m

Net Change in Cash

(2.3m)(4.2m)(5.8m)2.0m4.0m1.8m(1.6m)(2.6m)3.0m11.7m7.2m4.9m(3.0m)1.5m(729.5k)27.0m24.4m20.2m(12.2m)(7.4m)(15.3m)

Free Cash Flow

(10.4m)

Matinas BioPharma Ratios

USDQ1, 2014

Financial Leverage

1.1 x